+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

B

Actively Recruiting

Researchers are evaluating the effects of combining two drugs, cabozantinib and nivolumab, in treating patients with advanced melanoma or squamous cell head and neck cancer that may have spread to nearby tissues, lymph nodes, or distant parts of the body. This phase II study aims to assess how quickly patients can be grouped based on tumor biomarkers called tumor mutational burden and tumor inflammation signature, and to learn if the combination can shrink or stabilize the cancer depending on these biomarker statuses. Participants receive nivolumab through an intravenous infusion on the first day of each 28-day treatment cycle and take cabozantinib orally daily. Treatment cycles continue for up to two years unless the cancer progresses or unacceptable side effects occur. Throughout the trial, patients undergo CT or MRI scans and blood sample collections. Tumor biopsies are taken during screening and optionally during follow-up. After completing treatment, participants are followed up every 12 weeks for one year and then every six months up to three years after registration. During the study, patients will be monitored with imaging scans and laboratory tests to assess tumor response and safety. Researchers will measure how quickly biomarker results are available and evaluate overall response rates, disease control, progression-free survival, and overall survival over two years. Safety and tolerability of the drug combination will also be assessed, along with the identification of biomarkers that might predict treatment response or side effects. Specimens will be collected and stored for future research.

Age: 18Years +All GendersPhase 2
232 locations
C

Actively Recruiting

Researchers are studying how to best monitor pancreatic cysts and identify biomarkers that may signal the risk of these cysts developing into pancreatic cancer. The study compares two different monitoring approaches with varying frequencies, aiming to learn which method and biomarkers help improve patient outcomes. This observational study focuses on adults aged 50 to 75 who have pancreatic cysts detected by imaging. Participants undergo either low-intensity or high-intensity surveillance programs. The low-intensity group receives MRI, CT, or endoscopic ultrasound EUS scans initially and at intervals up to every two years depending on findings. The high-intensity group has more frequent imaging based on cyst size, including regular MRI, CT, and EUS scans. Blood samples, biopsies, and fine-needle aspirations may also be collected as needed. The study follows patients for 5 years from enrollment. During the trial, participants have regular imaging tests such as MRI, CT, and EUS, along with blood sample collections to assess biomarkers related to cyst changes. Researchers monitor clinical outcomes including the development of worrisome or high-risk features, quality of life, anxiety, financial distress, and healthcare costs. The study also tracks adherence to surveillance and surgical outcomes. Follow-up continues for 5 years to capture long-term results and identify factors linked to pancreatic cyst progression.

Age: 50Years - 75YearsAll Genders
429 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
S

Actively Recruiting

Researchers are evaluating a treatment approach for patients with locally advanced cervical cancer that has spread to nearby tissues or lymph nodes. This phase III trial compares the addition of induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before the usual chemotherapy and radiation treatment combined with pembrolizumab, followed by pembrolizumab maintenance. The study aims to determine if adding induction therapy improves progression-free survival and overall survival, while assessing safety and biomarkers related to treatment response. Participants are randomly assigned to one of two groups. One group receives standard chemoradiation with cisplatin and pembrolizumab followed by pembrolizumab maintenance. The other group receives induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before starting chemoradiation and pembrolizumab maintenance. Chemoradiation includes weekly cisplatin, radiation therapy daily for 5 weeks, and brachytherapy treatments. Pembrolizumab is given intravenously at different intervals during the treatment and maintenance phases. Throughout the study, participants undergo various imaging scans such as PET, CT, chest x-ray, and MRI, along with blood sample collections to monitor their condition. Researchers evaluate outcomes including progression-free survival, overall survival, treatment side effects, treatment completion times, and biomarker levels. After completing treatments, participants are followed up every 3 months for 2 years, then every 6 months for 3 more years to monitor long-term effects and disease status.

Age: 18Years +FEMALEPhase 3
346 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Cretostimogene Grenadenorepvec in people with high-risk non-muscle-invasive bladder cancer NMIBC. This Phase 2, multi-arm, open-label study includes participants who are either new to Bacillus Calmette-Guerin BCG treatment, previously treated with BCG, or unresponsive to BCG. The study aims to compare different administration methods and combinations with gemcitabine to better understand treatment options for this condition. Participants are divided into several groups based on their disease status and prior BCG treatment. The study drug Cretostimogene is administered directly into the bladder weekly for six weeks as an induction course, followed by reinduction for certain participants. Maintenance treatment involves cycles of three weekly doses every three months in the first year and every six months in the second year, with an optional extension to the third year. Some groups receive Cretostimogene alone, while others receive it combined with gemcitabine through alternative instillation methods. Participants will have their disease status monitored through urine tests, bladder visualizations like cystoscopy, upper urinary tract assessments, and biopsies if needed every three months for two years, then every six months for up to an additional two years or until disease recurrence. The study measures include complete response rates, event-free survival, and safety outcomes over periods ranging from weeks to 48 months. Overall participation may last several years, with careful follow-up to assess treatment impact and safety.

Age: 18Years +All GendersPhase 2
80 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the iTind device compared to the UroLift system for men experiencing lower urinary tract symptoms caused by benign prostatic hyperplasia BPH. Both devices offer minimally invasive treatment options, with iTind being a temporary implant that reshapes the urethra over 5 to 7 days, while UroLift involves permanent implants to widen the urethral opening. This study aims to directly compare these two methods to better understand their benefits and safety profiles. Participants are randomly assigned to receive either the iTind device, which is temporarily placed for 5 to 7 days, or the UroLift system, which places permanent implants in the prostate. The study evaluates changes in urinary symptoms and quality of life over several months, with follow-up assessments extending up to 36 months. Researchers monitor adverse events related to the procedure or devices and compare the need for additional interventions between the two groups. During the study, participants will complete questionnaires and undergo evaluations at baseline and multiple follow-up visits up to three years. Key measurements include the International Prostate Symptom Score IPSS to assess urinary symptoms and quality of life scores. Safety is closely monitored throughout the first three months post-procedure, and longer-term outcomes like symptom improvement and device-related events are tracked over time. Overall participation may last several years to gather comprehensive data on both treatments.

Age: 50Years +MALEPhase Not Applicable
19 locations
E

Actively Recruiting

Healthy Volunteer

Sexual and gender minority SGM populations face higher mental health challenges compared to their heterosexual and cisgender peers but often experience unmet mental health needs due to barriers in accessing care. Digital Mental Health DMH services offer a promising and cost-effective way to increase access to mental health care for these groups. This study evaluates tailored engagement strategies designed to increase how SGM users engage with free, evidence-based DMH resources offered by Mental Health America MHA through a micro-randomized trial MRT approach. Participants who complete an online depression screening PHQ-9 on the MHA website and identify as SGM will be randomized at two key points in the user flow to receive or not receive engagement strategies based on the Health Action Process Approach HAPA. These strategies target behavioral factors like outcome expectancy, self-efficacy, perceived risk, and barriersresources and are delivered as inline messages or cards on the Results page and targeted Next Steps resource page. The study may iteratively refine engagement strategies based on ongoing results during the trial period. Participants involvement includes completing the online PHQ-9 and demographic questions, then experiencing random assignment to different engagement strategies within their web session on the MHA site. Engagement is measured by click-through rates to resources, time spent on pages, and responses to outcome questions about helpfulness and confidence. All data is collected automatically through the websites analytics, with sessions capped at 30 minutes inactivity. The study runs from March 2026 to May 2027 and is designed to understand and improve how SGM users interact with digital mental health services.

Age: 14Years +All GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are evaluating intravesical Recombinant Mycobacterium Bacillus Calmette-Gue9rin rMBCG in adults with non-muscle invasive bladder cancer NMIBC who have not previously received BCG treatment. This phase 12, open-label, multicenter study focuses on participants with confirmed carcinoma in situ CIS or primaryrecurrent stage Ta andor T1 papillary tumors following transurethral resection. The study aims to assess the safety and effects of this biological treatment in this patient group. Participants will receive an induction course of rMBCG administered directly into the bladder via a urinary catheter. The dose consists of 1 vial containing 19.2e8 colony-forming units CFU delivered intravesically. This single-arm study monitors participants through the treatment phase to evaluate safety outcomes over approximately seven months. During the study, participants will be closely monitored for safety by tracking the incidence and severity of adverse events. Evaluations include clinical assessments and laboratory tests at regular intervals. Participants must provide written consent and agree to comply with study procedures and follow-up evaluations. The total duration includes the treatment period and safety observation lasting about seven months.

Age: 18Years - 85YearsAll GendersPhase 1Phase 2
9 locations
R

Actively Recruiting

Researchers are evaluating dose-escalated radiation therapy compared to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have already received 4 to 8 months of chemotherapy. The study aims to determine if this higher-dose radiation can improve 3-year overall survival compared to standard therapies such as continued chemotherapy, observation, or standard radiation. The trial also assesses progression, chemotherapy-free intervals, toxicity, and quality of life measures. Participants are randomly assigned to either standard care, which includes options like continued chemotherapy regimens FOLFIRINOX, NALIRIFOX, or gemcitabinenab-paclitaxel, standard radiation therapy with concurrent chemotherapy, or observation, or to dose-escalated radiation therapy delivered in either a 5-fraction or 25-fraction regimen with or without concurrent chemotherapy. Blood samples, CT scans, MRI, and tumor biopsies are collected throughout the study. Optional PETCT scans may be performed before treatment. Participants are followed with regular assessments every 3 months for 2 years, then annually for 3 more years. Researchers monitor overall survival, local tumor progression, progression-free survival, chemotherapy-free intervals, adverse events, and quality of life using standardized questionnaires. Biospecimens are also collected for future analysis. The total study duration spans up to 5 years of follow-up after randomization.

Age: 18Years +All GendersPhase 3
333 locations

1-10 of 15

1